We and others have previously demonstrated that STAT3 signaling in response to IL-6 family cytokines provides a rate-limiting signal for gastrointestinal tumors that arise from bona fide oncogenic driver mutations, including in APC, KRAS, or other genes.20 This evidence concerns the gene STAT3 and digestive system neoplasm.